항체 위탁개발생산기관 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 공급원별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)
Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030
상품코드
:
1362984
리서치사
:
Grand View Research, Inc.
발행일
:
2023년 09월
페이지 정보
:
영문 175 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
항체 CDMO(항체 위탁개발생산기관) 시장 성장 및 동향:
Grand View Research, Inc.의 최신 보고서에 따르면 세계 항체 CDMO 시장은 2023년부터 2030년까지 14.0%의 CAGR로 성장하여 2030년에는 584억 달러에 달할 것으로 예상됩니다.
항체 CDMO 시장의 성장을 촉진하는 주요 요인은 새로운 항체 치료제 발견을 위한 연구개발 활동의 발전, 암 환자 증가, CDMO와 바이오제약 기업 간의 협력 관계의 증가입니다.
항체는 약물요법이며, 특히 암 치료에 사용됩니다. 이 항체는 신체의 건강한 세포에 영향을 미치지 않고 약물의 치료 지수를 향상시켰습니다. 이것이 암 치료에서 항체에 대한 수요가 높은 두 가지 주요 이유입니다. 이러한 요인들은 임상 연구에서 항체 약물 복합체(ADC)와 같은 항체 유형의 개발을 지원하고 있습니다.
항체가 암 치료에서 높은 효율을 보임에 따라 바이오제약 기업들은 항체 관련 연구를 위해 많은 자금 지원을 받고 있습니다. 예를 들어, 2022년 10월 Mablink Bioscience는 암 치료용 항체 ADC 파이프라인을 구축하기 위해 시리즈 A 펀딩을 통해 3,100만 달러를 조달했습니다. 마찬가지로 2021년 7월, ProfoundBio는 항체 ADC 파이프라인 개발을 가속화하기 위해 투자자로부터 5,500만 달러를 투자받았습니다. 따라서 암 치료와 관련된 새로운 치료제를 개발하기 위한 바이오 제약 기업의 노력이 증가하는 것은 시장 성장을 뒷받침하는 주요 요인 중 하나입니다.
COVID-19의 대유행은 시장에 큰 영향을 미쳤습니다. 그러나 일부 기업은 파트너십, 합병, 인수 등 조직 내 전략적 이니셔티브를 채택하여 전염병의 영향을 완화하고 판매 수익을 회복하기 위해 노력했습니다. 또한 우크라이나와 러시아 간의 지정학적 전쟁은 항체 CDMO 시장에 부정적인 영향을 미치고 있습니다. 이는 미국과 같은 특정 국가에 큰 영향을 미치고 있으며, 이로 인해 2022년 동안 세계 시장 전체 수익이 완만하게 하락할 것으로 예상됩니다.
항체 CDMO 시장 보고서 하이라이트
- 모노클로날 항체 부문은 2022년 67.6%의 가장 큰 점유율을 차지했습니다. 이 부문은 항암제 기반 모노클로날 항체 치료제에 대한 수요 증가에 힘입어 전체 항체 치료제의 대부분을 차지하고 있습니다.
- 유래별로는 포유류 부문이 2022년 58.5%로 가장 큰 점유율을 차지했습니다. 이 부문의 높은 점유율은 전체 포유류 항체 치료제에서 아웃소싱 비중이 증가하고 있기 때문입니다. 따라서 CDMO는 자체 생산보다 상대적으로 저렴한 비용으로 제조 서비스를 제공하고 있으며, 이는 시장 점유율을 높이는 데 기여하고 있습니다.
- 면역 매개 질환 분야는 예측 기간 동안 가장 빠른 CAGR 14.6%로 성장할 것으로 예상됩니다. 이는 면역 매개 질환 치료에서 새로운 항체를 발견하기 위한 임상시험의 비율이 증가하고 있기 때문입니다.
- 바이오제약 기업은 2023년부터 2030년까지 가장 빠른 CAGR 14.3%로 성장할 것으로 예상됩니다. 이는 새로운 항체 치료제 생산에 집중하는 바이오 제약 기업이 증가함에 따라 예측 기간 동안 유리한 성장을 뒷받침할 것으로 보입니다.
- 아시아태평양은 예측 기간 동안 14.2%의 가장 높은 CAGR로 성장할 것으로 예상됩니다. 높은 성장의 주요 원인은 인도, 중국 등 아시아 국가들의 생산 비용이 유럽과 미국보다 상대적으로 낮기 때문에 이 지역 전체에서 더 많은 고객층을 끌어들이고 이 지역의 성장을 뒷받침하고 있기 때문입니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 항체 CDMO 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 항체 CDMO 시장 분석 툴
- 업계 분석 - Porter's Five Forces 분석
- PESTEL 분석
- COVID-19 감염증의 영향 분석
- 항체 조사를 위한 임상시험량 분석,(2022)
- 규제 상황 :
제4장 항체 CDMO 시장 : 제품 추정·동향 분석
- 항체 CDMO 시장, 제품별 : 부문 대시보드
- 항체 CDMO 시장, 제품별 : 변동 분석
제5장 항체 CDMO 시장 : 공급원 추정·동향 분석
- 항체 CDMO 시장, 공급원별 : 부문 대시보드
- 항체 CDMO 시장, 공급원별 : 변동 분석
제6장 항체 CDMO 시장 : 치료 분야 추정·동향 분석
- 항체 CDMO 시장, 치료 분야별 : 부문 대시보드
- 항체 CDMO 시장, 치료 분야별 : 변동 분석
제7장 항체 CDMO 시장 : 최종 용도 추정·동향 분석
- 항체 CDMO 시장, 최종 용도별 : 부문 대시보드
- 항체 CDMO 시장, 최종 용도별 : 변동 분석
제8장 항체 CDMO 시장 : 지역 추정·동향 분석
- 지역 시장 점유율 분석, 2022년 및 2030년
- 지역 시장 대시보드
- 세계의 지역 시장 현황
- 북미
- 시장 추정과 예측, 2018-2030년
- 미국
- 캐나다
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제9장 경쟁 상황
- 시장 진출 기업 분류
- 이노베이터
- 시장 리더
- 신흥 기업
- 기업의 시장 점유율 분석, 2022년
- 기업 개요
- Lonza
- Catalent, Inc
- Samsung Biologics
- WuXi Biologics
- AGC Biologics
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Charles River Laboratories
- FUJIFILM Holdings Corporation
- mAbxience
ksm
영문 목차
Antibody CDMO Market Growth & Trends:
The global antibody CDMO market is expected to reach USD 58.40 billion by 2030, expanding at a CAGR of 14.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.
Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.
Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.
The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.
Antibody CDMO Market Report Highlights:
- Monoclonal antibodies segment accounted for the largest share of 67.6% in 2022.The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics
- Based on the source, the mammalian segment accounted for the largest share of 58.5% in 2022. High shares of the segment are majorly due to increasing rates of outsourcing witnessed across mammalian antibody therapeutics, as the cost of production of such antibodies is significantly high. Hence, CDMOs offer these manufacturing services at a comparatively lower cost than in-house production rates, thus supporting its large segment share in the market
- The immune-mediated disorders segment is anticipated to register the fastest CAGR of 14.6% during the forecast period. This is due to the growing rate of clinical trials targeted at discovering novel antibodies in the treatment of immune-mediated disorders
- Biopharmaceutical companies are anticipated to register the fastest CAGR of 14.3% from 2023 to 2030, owing increasing number of biopharmaceutical companies focusing on producing novel antibody therapeutics, thus supporting its lucrative growth during the forecast period
- Asia Pacific is anticipated to witness the highest CAGR of 14.2% during the forecast time frame. High growth is majorly due to Asian countries such as India and China, where the cost of production is comparatively lower than in Western economies, thus attracting a larger customer base across the region and thereby supporting the region's growth
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
- 1.1.2. Product
- 1.1.3. Source
- 1.1.4. Therapeutic Area
- 1.1.5. End Use
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective-1
- 1.4.2. Objective-2
- 1.4.3. Objective-3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
- 1.10. List Of Secondary Sources
- 1.11. List Of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Antibody CDMO Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Antibody CDMO Services
- 3.2.1.2. Rising Incidence of Cancer
- 3.2.1.3. High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing Contributing to Demand For Outsourcing Services
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Quality Issues While Outsourcing
- 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
- 3.3. Antibody CDMO Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat Of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- 3.3.4. Clinical Trial Volume Analysis for Antibody Research, (2022)
- 3.3.5. Regulatory Landscape:
- 3.3.5.1. U.S.
- 3.3.5.2. Europe
- 3.3.5.3. Asia Pacific
- 3.3.5.4. Rest of the World
Chapter 4. Antibody CDMO Market: Product Estimates & Trend Analysis
- 4.1. Antibody CDMO Market, By Product: Segment Dashboard
- 4.2. Antibody CDMO Market, By Product: Movement Analysis
- 4.3. Antibody CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
- 4.3.1. Monoclonal Antibodies
- 4.3.1.1. Monoclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
- 4.3.2. Polyclonal Antibodies
- 4.3.2.1. Polyclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
- 4.3.3. Others
- 4.3.3.1. Others Antibody CDMO Market, 2018 to 2030, (USD Million)
Chapter 5. Antibody CDMO Market: Source Estimates & Trend Analysis
- 5.1. Antibody CDMO Market, By Source: Segment Dashboard
- 5.2. Antibody CDMO Market, By Source: Movement Analysis
- 5.3. Antibody CDMO Market Estimates & Forecasts, By Source, 2018 - 2030
- 5.3.1. Mammalian
- 5.3.1.1. Mammalian Antibody CDMO Market, 2018 to 2030 (USD Million)
- 5.3.2. Microbial
- 5.3.2.1. Microbial Antibody CDMO Market, 2018 to 2030, (USD Million)
Chapter 6. Antibody CDMO Market: Therapeutic Area Estimates & Trend Analysis
- 6.1. Antibody CDMO Market, By Therapeutic Area: Segment Dashboard
- 6.2. Antibody CDMO Market, By Therapeutic Area: Movement Analysis
- 6.3. Antibody CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
- 6.3.1. Oncology
- 6.3.1.1. Oncology Antibody CDMO Market 2018 to 2030 (USD Million)
- 6.3.2. Neurology
- 6.3.2.1. Neurology Antibody CDMO Market 2018 to 2030 (USD Million)
- 6.3.3. Cardiology
- 6.3.3.1. Cardiology Antibody CDMO Market 2018 to 2030 (USD Million)
- 6.3.4. Infectious Diseases
- 6.3.4.1. Infectious Diseases Antibody CDMO Market 2018 to 2030 (USD Million)
- 6.3.5. Immune-mediated Disorders
- 6.3.5.1. Immune-mediated Disorders Antibody CDMO Market 2018 to 2030 (USD Million)
- 6.3.6. Others
- 6.3.6.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)
Chapter 7. Antibody CDMO Market: End Use Estimates & Trend Analysis
- 7.1. Antibody CDMO Market, By End Use: Segment Dashboard
- 7.2. Antibody CDMO Market, By End Use: Movement Analysis
- 7.3. Antibody CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
- 7.3.1. Biopharmaceutical Companies
- 7.3.1.1. Biopharmaceutical Companies Antibody CDMO Market 2018 to 2030 (USD Million)
- 7.3.2. Research Laboratories
- 7.3.2.1. Research Laboratories Antibody CDMO Market 2018 to 2030 (USD Million)
- 7.3.3. Others
- 7.3.3.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)
Chapter 8. Antibody CDMO Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2022 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. North America
- 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
- 8.5. Europe
- 8.5.1. UK
- 8.5.1.1. Key Country Dynamics
- 8.5.1.2. Competitive Scenario
- 8.5.1.3. Regulatory Framework
- 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
- 8.5.2. Germany
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 8.5.3. France
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 8.5.4. Italy
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 8.5.5. Spain
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Competitive Scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 8.5.6. Denmark
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Competitive Scenario
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
- 8.5.7. Sweden
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Competitive Scenario
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 8.5.8. Norway
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Competitive Scenario
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
- 8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.1.1. Key Country Dynamics
- 8.6.1.2. Competitive Scenario
- 8.6.1.3. Regulatory Framework
- 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
- 8.6.2. India
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
- 8.6.4. South Korea
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
- 8.6.6. Thailand
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
- 8.7. Latin America
- 8.7.1. Brazil
- 8.7.1.1. Key Country Dynamics
- 8.7.1.2. Competitive Scenario
- 8.7.1.3. Regulatory Framework
- 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
- 8.7.2. Mexico
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
- 8.8. MEA
- 8.8.1. South Africa
- 8.8.1.1. Key Country Dynamics
- 8.8.1.2. Competitive Scenario
- 8.8.1.3. Regulatory Framework
- 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 8.8.2. Saudi Arabia
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 8.8.3. UAE
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 8.8.4. Kuwait
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Competitive Scenario
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.1.1. Innovators
- 9.1.2. Market Leaders
- 9.1.3. Emerging Players
- 9.1.4. Company Market Share Analysis, 2022
- 9.2. Company Profiles
- 9.2.1. Lonza
- 9.2.1.1. Company Overview
- 9.2.1.2. Financial Performance
- 9.2.1.3. Service Benchmarking
- 9.2.1.4. Strategic Initiatives
- 9.2.2. Catalent, Inc
- 9.2.2.1. Company Overview
- 9.2.2.2. Financial Performance
- 9.2.2.3. Service Benchmarking
- 9.2.2.4. Strategic Initiatives
- 9.2.3. Samsung Biologics
- 9.2.3.1. Company Overview
- 9.2.3.2. Financial Performance
- 9.2.3.3. Service Benchmarking
- 9.2.3.4. Strategic Initiatives
- 9.2.4. WuXi Biologics
- 9.2.4.1. Company Overview
- 9.2.4.2. Financial Performance
- 9.2.4.3. Service Benchmarking
- 9.2.4.4. Strategic Initiatives
- 9.2.5. AGC Biologics
- 9.2.5.1. Company Overview
- 9.2.5.2. Financial Performance
- 9.2.5.3. Service Benchmarking
- 9.2.5.4. Strategic Initiatives
- 9.2.6. AbbVie Inc.
- 9.2.6.1. Company Overview
- 9.2.6.2. Financial Performance
- 9.2.6.3. Service Benchmarking
- 9.2.6.4. Strategic Initiatives
- 9.2.7. Boehringer Ingelheim International GmbH
- 9.2.7.1. Company Overview
- 9.2.7.2. Financial Performance
- 9.2.7.3. Service Benchmarking
- 9.2.7.4. Strategic Initiatives
- 9.2.8. Charles River Laboratories
- 9.2.8.1. Company Overview
- 9.2.8.2. Financial Performance
- 9.2.8.3. Service Benchmarking
- 9.2.8.4. Strategic Initiatives
- 9.2.9. FUJIFILM Holdings Corporation
- 9.2.9.1. Company Overview
- 9.2.9.2. Financial Performance
- 9.2.9.3. Service Benchmarking
- 9.2.9.4. Strategic Initiatives
- 9.2.10. mAbxience
- 9.2.10.1. Company Overview
- 9.2.10.2. Financial Performance
- 9.2.10.3. Service Benchmarking
- 9.2.10.4. Strategic Initiatives
관련자료
